As therapies become increasingly personalized, technically demanding and costly to develop, we recognize that a purely transactional manufacturing model falls short of providing the deep technical expertise, regulatory fluency, and operational agility required to deliver high-quality, life-enhancing products to patients. The demands on innovators in the manufacturing partnership space require new levels of flexibility in engaging with partners throughout the process, and Emergent is in a unique position to do that.
Emergent isn’t a traditional contract development and manufacturing organization (CDMO). Instead, we build lasting, highly flexible manufacturing partnerships, leveraging our deep industry knowledge, technologies, and capabilities, working in lockstep with our partners, to bring their life-saving solutions to communities around the world.
Our approach to strategic manufacturing partnerships
At Emergent, we move beyond transactional manufacturing by investing in the journey alongside our clients. Our bespoke, versatile partnership models meet the specialized needs of biopharma innovators through in-house manufacturing and containment capabilities. By tailoring our approach to partners’ project needs, we serve as an extension of your team, helping develop, manufacture, and deliver solutions to complex global health problems. 
We have unique capabilities in the most constrained environments, whether that is dealing with plasma products, BSL2 and BSL3, or managing relationships with government agencies for clients. The distinct advantages we deliver in our partnerships include efficient tech transfer, flexible and scalable Current Good Manufacturing Practices (cGMP) solutions, commitment to quality and commercial compliance, and collaborative thinking.
Throughout the process, we emphasize quality, compliance and operational excellence.
Our advanced and comprehensive capabilities
Emergent has four manufacturing facilities across North America, with decades of experience in strategic manufacturing supporting biopharma innovators, governments, and non-governmental organizations.
Our facilities are located in:
- Rockville, Maryland
- Canton, Massachusetts
- Lansing, Michigan
- Winnipeg, Manitoba, Canada
Emergent’s Winnipeg facility stands at the forefront of integrated plasma product and biotherapeutic manufacturing. With over 45 years of operational experience, it has supported more than a dozen commercial products.
As a strategic manufacturing partner, Emergent offers advanced and comprehensive capabilities to bring our partners’ products to life. These capabilities include, but are not limited to:
Analytical development and testing services: 
- Drug substance manufacturing of plasma proteins and complex biologics
- Aseptic fill/finish using isolator-based equipment
- Containment and handling of BSL-2 and BSL-3 level products
Our work in action
We know it takes a unified team to develop and deliver highly sophisticated products to address some of the world’s deadliest threats. That’s why Emergent is committed to building long-lasting strategic manufacturing partnerships.
The biopharmaceutical industry faces increasingly complex challenges, and at Emergent, we are tackling those challenges together.
To learn more about how we can partner on your manufacturing needs, visit: emergentbiosolutions.com/partnerships.